Indication intelligence, analysis and sector perception

Biostage (BSTG) just another junk trade or a bankruptcy?

October 13, 2017 11:29am

Are day traders ready for the filed 8-K as BSTG conducted a reduction in headcount …

… Of 17 of its employees, which represented 71% of its work force… the reduction and other cost cutting measures are to explore strategic alternatives – bankruptcy? Pecos, its proposed investor has also demanded that BSTG pay a $500 K termination fee pursuant to the terms of “their” agreement.

The biggest issue is WHY the CEO and CFO are maintaining their HIGH salaries and bennies being the root and cause of BSTG’s demise – their tactical execution. As I said last night in my opinion, where is the SEC when shareholders need them?

Who is left, a CEO, a CFO and 2 accountants and a systems guy – tell me about the science and regulatory initiative as even LM (a class act), the VP Regulatory quit 2 weeks ago with NO 8-K filed. Do you really think – this gang that didn’t and couldn’t shoot straight will be able to return – ANYTHING to shareholders?

$0.10 on Friday – the 13^th, wait for the $0.03 …

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.